The effects of interleukin-2 (IL-2) on various models of experimental epilepsy were studied after intracerebroventricular administration in DBA/2 mice, a strain genetically susceptible to sound-induced seizures. Convulsions were induced by physical stimulus (sound of 109 dB, 12-16 kHz) or by chemical compounds (bicuculline, cephazolin or kainate). The present study demonstrated that human recombinant IL-2 (hr-IL-2) and mouse recombinant IL-2 (mr-IL-2) not only did not antagonize audiogenic seizures in DBA/2 mice but increased the incidence of seizures after the highest doses studied. In addition, hr-IL-2 and mr-IL-2 dose dependency facilitated sound-induced seizures at subthreshold sound exposure (8 3 dB). Pretreatment with monoclonal rat-anti-mouse IL-2 antibodies significantly affected the changes of occurrence of audiogenic seizures in DBA/2 mice induced by mr-IL-2. In addition, pretreatment with anti-IL-2 receptor monoclonal antibodies (anti-Tac) was able to completely antagonize or reduce the effects of IL-2 on audiogenic seizures. The effects of mr-IL-2 were also studied in two different models of epilepsy: the bicuculline and cephazolin models, due to impairment of GABAergic transmission, and the kainate model, due to an increase in excitatory amino acid transmission. In all models, mr-ILr2 demonstrated to facilitate the seizures induced by these chemoconvulsants. Since the proconvulsant properties of IL-2 were antagonized by specific monoclonal antibodies, we suggest that some epileptic phenomena may be linked to stimulation of IL-2 receptors. Further experiments will be necessary in order to ascertain whether IL-2 acts via the potentialization of the effects of excitatory amino acids or via inhibition of GABA activity, or both in the brain.
Introduction
Interleukin-2 (IL-2) is a small single-chain soluble protein (M r 15,500). The structure of 11^2 has been characterized by means of X-ray cristallography; the 133 amino acids in the protein backbone of the molecule appear to be coiled and folded into a roughly spheric shape [1, 2] . The structure, organization and amino acid sequence of 11^2 receptors have been characterized on the membrane of T lymphocytes [3, 4] . 11^2 enhances T-lymphocyte prolifer= Rectal temperature was recorded immediately prior to auditory testing using an Elek-trolaboratoriet thermometer type TE 3. Behavioral changes were observed during the period between drug administration and auditory testing.
Testing of Anticonvulsant Activity Against Chemoconvulsants DBA/2 mice (6-12 g, 21-26 days old or 16-24 g, 42-48 days old) were purchased from Charles River (Calco, Como, Italy). Mice were injected intraperitoneally (i.p.) with cephazolin (0.1-2.0 g/kg) dissolved in sterile saline or bicuculline methiodide subcutaneously (s.c.) or i.c.v. dissolved in a minimal quantity 0.2 N HC1 and adjusted to pH 5.3 by adding 0.2 N NaOH and then saline. Kainic acid was dissolved in sodium phosphate buffer. Animals were placed in a Plexiglas box (40 x 40 x 30 cm) and observed for 240 min after i.p. or s.c. administration or 120 min after i.c.v. injection of chemoconvulsants. For systemic injections, all compounds were administered with 0.1 ml/10 gofbody weight of the mouse. For each dose of cephazolin or bicuculline, 10 animals were used. The intensity of SR was scored on the following scale: 0 = no response, 1 = wild running, 2 = clonus, 3 = tonus, 4 = respiratory arrest, which is identical to that observed after auditory stimulation [26] . For each dose of kainate, 8-10 animals wer^used. A second group of animals was treated i.c.v;%ith IL-2 at a dose of 1.35, 2.7 pmol/mouse or vehicle and 15 min later the same animals were injected i.p. with various doses of cephazolin, kainate or bicuculline. At the dose of 1.35 pmol injected i.c.v., each IL-2 was unable to elicit seizures in DBA/2 mice and elicited a mild decrease in spontaneous activity and explorative behavior.
ECoG Analysis
ECoG activity was recorded (8-channel ECoG machine OTE Biomedica, Florence, Italy) through 4 chronically implanted steel screw electrodes, inserted bilaterally into the fronto-parietal area. The ground electrode was implanted epidurally over nasal bone; at least 3 mice, treated with the largest dose of vehicle + cephazolin, IL-2 + cephazolin, vehicle + bicuculline, or IL-2 + bicuculline, were studied for changes in ECoG activity.
Statistical Analysis
Statistical comparisons among groups of control and drug-treated animals were made using Fisher's exact probability test (incidence of the seizure phases) or ANOVA and Dunnett's t test (rectal temperaiino/Gratteri/Nistic6 Proconvulsant Effects of IL-2 Groups of DBA/2 mice were injected i.cv. with the stated doses of the drugs or vehicle and exposed to auditory stimulation 30 min after drug injection. The incidence of each seizure phase is expressed as the percentage of mice in each group displaying that phase. WR = Wild running; RA = respiratory arrest; SR = the arithmetic mean of the maximal individual responses for each animal in the group; Temp. = rectal temperature measured immediately before auditory stimulation; n = number of animals used. tures). The percentage incidence of each phase of the AGS was determined for each dose of compound administered and long dose-response curves were fitted using linear regression analysis of probits. ED 50 values (with 95% confidence limits) for each compound and each phase of SR were estimated using the method of probit analysis [27] ; the relative convulsant activities were also determined by comparison of respective ED50 values.
Drugs
The sources of the drugs used were: recombinant human interleu-kin-2 (hr-11^2), recombinant mouse-interleukin-2 (mr-11^2), kainic acid and bicuculline methiodide were purchased from Sigma (St. Louis, Mo., USA), anti-11^2 receptor monoclonal antibodies (anti-Tac) and monoclonal rat anti-mouse-IL-2 antibodies (mo-Abs-H^2) were purchased from Genzyme (Cambridge, Mass., USA), while cephazolin was obtained from Carlo Erba Farmitalia (Milan, Italy). mr-IL-2 was also denaturated at 70 °C for 30 min and used as control. For i.cv. injections, mice were anesthetized with ether and injections were made in the left or right lateral ventricle (coordinates 1 mm posterior and 1 mm lateral to the bregma; depth 2.4 mm) using a 10-ul Hamilton microsyringe (type 701N) fitted with a Nylon cuff on the needle, as previously described [28] . Injections of the drugs by this procedure led to a uniform distribution throughout the ventricular system within 10 min [28] .
Results
Effects ofIL-2 on Audiogenic Seizures in DBA/2 Mice hr-H^2 (0.14, 0.27, 1.35, 2.7 and 13.5pmol/mouse), mr-II^2 (0.14, 0.27, 1.35, 2.7 and 13.5 pmol/mouse) administered i.cv. did not decrease the severity of the AGSs in DBA/2 mice (table 1) but, at the highest doses studied, increased the severity of seizures. In particular, after a latency period of 7-10 min at the doses of 2.7 and 13.5 pmol injected i.cv., mice showed jumping, increase in locomotor activity, marked tremor, clonus of forelimbs and hindlimbs. Tonic convulsions were observed in 4 out of 14 and 6 out of 16 animals treated with 13.5 pmol of hr-II^2 and mr-IL-2, respectively. Tonic extension followed by respiratory arrest and death of the animal was seen in 2 out of 14 and 4 out of 16 mice treated with 13.5 pmol of hr-IL-2 and mr-IL-2, respectively.
In previous studies, we demonstrated that a pretreat-ment (15 min before) with mo-Abs-II^2 was able to block the effects of H^2. This was a clear proof that mo-Abs-II^2 reached the 11^2 receptors and were not degraded by proteases present at the surface of the brain or by peptidases present in the ventricular spaces. In addition, the antagonism with mo-Abs-IL-2 demonstrated that the IL-2 effects were directly mediated [29] . Mo-Abs-IL-2 (10, 50 and 363 Table 2 . Effects of i.c.v. administration of mo-Abs-IL-2 and mr-IL-2 in DBA/2 mice Groups of DBA/2 mice were injected jB?. with the stated doses of the drugs or vehicle and exposed to auditory stimulation 40 min after mo-Abs-IL-2 injection (ng/mouse). The incidence of each seizure phase is expressed as the percentage of mice in each group displaying that phase. Significant differences in the incidence of seizure phases between concurrent control (mr-IL-2) and drugtreated groups (mo-Abs-IL-2 + mr-IL-2) are denoted: * p &amp;lt; 0.05; ** p &amp;lt; 0.01. The abbreviations used in the headings are explained in the footnote of table 1.
De Sarro/Rotiroti/Audino/Gratteri/Nistic6 Proconvulsant Effects of JDL-2 Groups of DBA/2 mice were injected i.c.v. with the stated doses of the drugs or vehicle and exposed to auditory stimulation 30 min after denaturated mr-IL-2 or 40 min after anti-Tac injection (ng/mouse). The incidence of each seizure phase is expressed as the percentage of mice in each group displaying that phase. Significant differences in the incidence of seizure phases between concurrent control (mr-IL-2, table 3) and drug-treated group (anti-Tac + mr-VU-2) are denoted: * p &amp;lt; 0.05; ** p &amp;lt; 0.01. Den-mr-IL-2 = denaturated mr-II^2. The abbrevi-a t ions used in the headings are explained in the footnote to table 1.
100 ng/mouse i.c.v.) did not significantly modify the occurrence of AGSs in DBA/2 mice (table 2) . A pretreatment (10 min before) with mo-Abs-H^2 (50 and 100 ng/mouse) microinjected into a lateral ventricle did not significantly affect the incidence of the AGSs observed following the microinjection by the same route of mr-IL-2 (table 2) . In addition, hr-IL-2 and mr-IL-2 facilitated dose-dependently sound-induced seizures at a subthreshold sound exposure (83 dB) with an ED 50 for tonus of 1.35 forboth mr-II^2 and hr-IL2 (table 3) . A treatment with denaturated mr-IL-2 did not significantly affect the incidence of the audiogenic seizures elicited by a subthreshold sound exposure (83 dB) (table 4) . Mo-Abs-ILr2 (10, 50 and 100 ng/mouse, 5 ul i.c.v.) did not significantly affect the occurrence of AGSs in DBA/2 mice after exposure to a subthreshold stimulus of 83 dB. In addition, a pretreatment 10 min before with mo-Abs-IL2 (50 and 100 ng) microinjected into a lateral ventricle protected against the proconvulsant effects of mr-IL-2 observed with a subthreshold sound stimulus (83 dB) (table 3) . A pretreatment, 10 min before, with anti-Tac (50 and 100 ng/mouse i.c.v.) was able to antagonize or to reduce the effects of mr-II^2 on AGSs ( (table 6 ). In addition, the CD50 values of combined treatment of mr-IL-2 and bicuculline after systemic administration was 2.4 (2.2-2.7) mg/kg for tonus and 2.45 (2.2-2.7) mg/kg for the LD 50 (table 6) . (table 7) .
Effects ofIL-2 on Cephazolin-Induced Seizures

Electrocortical Activity in Mice
Electrocortical epileptic discharges appeared after a shorter latency period in mice pretreated with mr-ILr2 in comparison to those receiving^ehicle + cephazolin or bicuculline ( fig. 1, 2) . In addition the animals pretreated with mr-IL-2 showed ECoG epileptic discharges of a longer duration than those treated with vehicle + cephazolin or bicuculline (data not shown^Bowever, the ECoG epileptic features were similar in DBA/2 mice which received vehicle + bicuculline or mr-IL-2 + bicuculline and in animals which received vehicle + cephazolin or mr-IL-2 + cephazolin ( fig. 1,2) . 
Discussion
The results of the present study demonstrate that JL-2 given into the cerebral ventricles possesses a proconvul-sant activity. This was an unexpected effect since in previous experiments we have shown that IL-2 microinjected cerebrally possesses marked behavioral and ECoG sedative effects [11, 19, 29, 30] . However, large doses of 11^2 ^^Spinfused into the third cerebral ventricle or the dorsal hippocampus elicited electrical spiking activity associated with a frozen state or with wet dog shake episodes and rarely with clonic convulsions [11, 30] . These observations taken together with the present data suggest that IL-2 possesses different effects according to the dose and the site of microinjection, i.e. low doses are soporific and large doses are epileptogenic. The most sensitive area through which soporific effects were elicited was the locus ceruleus [11, 29, 30] , whereas the most sensitive area for the epileptogenic properties of IL-2 was the hippocampus [30] . Some other peptides applied in the hippocampus induce seizures [31] , whereas in other structures such as the locus ceruleus they are soporific [32] . The present study also confirms that the AGSs in DBA/2 mice represent a sensitive test for discriminating compounds with anticonvulsant or proconvulsant activity [16, 33] . Since the proconvulsant or convulsant properties of EL-2 were antagonized by mo-Abs-IL-2, it is possible to suppose that 11^2 acts directly through stimulation of specific receptors. The findings that anti-11^2 receptor monoclonal antibodies antagonized or reduced the effects of DL-2 on audiogenic seizures, seem to further support the previous hypothesis. It is also likely that 11^2 may interact indirectly with some neurotransmitters, but at the moment data are not available.
In previous experiments we have demonstrated that the monoclonal antibodies used were able to block the soporific effects elicited by the microinfusion of interleukins into the locus ceruleus [11, 12, 19, 29, 30] , suggesting that this technical approach is quite correct to block the effects of interleukins. Thus the findings of the effects of these antibodies tell us that some of epileptogenic effects of EL-2 are directly mediated. It is of interest that proconvulsant effects of 11^2 were obtained in two different models of epilepsy, the cephazolin and bicuculline model due to impairment of GABAergic transmission [ 19, 24] and the kainate model, due to an increase in excir-atory amino acid transmission [25] . In addition, the fact that the proconvulsant actffity of mr-IL-2 was more evident when bicuculline was administered directly into the brain than when it was given peripherally clearly suggests the presence of important interactions between the two compounds. In fact, the potentiation of convulsant properties of bicuculline was more easily elicited when both agents were present principally at the liquor of the ventricular spaces. Whereas it was less evident when IL-2 wal present prevalently at the liquor of the ventricular spaces and bicuculline, administered peripherally, was present in all brain. Furthermore, it appeared clear that the brain sites where 11^2 acts are close to ventricular spaces. Further experiments will be necessary in order to ascertain whether IL-2 preferentially acts potentiating the effects of excitatory amino acids or inhibiting GABAergic neurotransmission in the brain. The epileptogenic properties of 11^2 seem specifically linked to the stimulation of IL2 receptors since the specific mo-Abs-ILr2 or anti-Tac were able to prevent them. This indicates that the mechanisms underlying the increased excitability are very likely linked to TLr2 receptors, however an interference with other neurotransmitters cannot be excluded.
